ROCKVILLE, Md., Sept. 4 Human Genome Sciences,Inc. (Nasdaq: HGSI) today announced that it has entered into an exclusiveagreement with Hospira, Inc., for manufacturing process development andcommercial supply of select Hospira biopharmaceutical products. Financialterms were not disclosed, and specific products were not identified.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
"We look forward to using our company's world-class manufacturingfacilities, quality systems and process development capabilities to helpadvance and supply biopharmaceutical products for Hospira. We are pleased tobe chosen by a company of Hospira's stature for such an important role," saidCurran Simpson, Senior Vice President of Operations, HGS. "The priority focusof HGS continues to be the commercialization of our lead products. Agreementssuch as the one announced today will produce near-term revenue from availablemanufacturing capacity. We see potential for $30-60 million in revenue frommanufacturing alliances, including this alliance with Hospira, over the nextthree to four years."
Protein and antibody process development and manufacturing are core HGScompetencies. The Company currently produces several protein and antibodydrugs in two state-of-the-art cGMP-compliant process development andmanufacturing facilities -- totaling approximately 400,000 square feet andoffering both small-scale and large-scale production in batches from 650-20,000 liters.
"The manufacturing alliance with HGS is an excellent strategic partnershipfor both companies and is representative of Hospira's commitment to meetfuture demand for high-quality, cost-effective alternatives to proprietarybiopharmaceuticals," said John Lane, Vice President, Biologics, Hospira, Inc."By securing access to HGS' leading-edge technology in late-stage processdevelopment and large-scale biopharmaceutical manufacturing capability, wealso defer the immediate need to invest in additional Hospira facilities forthe manufacture of these biologic products."
In addition to the agreement with Hospira announced today, HGS enteredinto a marketing services agreement with Eden Biodesign Ltd. in mid-August2008, under which Eden Biodesign will assist HGS in identifying other large-scale manufacturing and late-stage process development clients.
Hospira, Inc. is a global specialty pharmaceutical and medication deliverycompany dedicated to Advancing Wellness(TM). As the world leader in specialtygeneric injectable pharmaceuticals, Hospira offers one of the broadestportfolios of generic acute-care and oncology injectables, as well asintegrated infusion therapy and medication management solutions. Through itsproducts, Hospira helps improve the safety, cost and productivity of patientcare. The company is headquartered in Lake Forest, Ill., and has more than14,000 employees. Learn more at www.hospira.com.
About Human Genome Sciences
The mission of HGS is to apply great science and great medicine to bringinnovative drugs to patients with unmet medical needs. The HGS clinicaldevelopment pipeline includes novel drugs to treat hepatitis C, lupus,inhalation anthrax, cancer and other immune-mediated diseases. The Company'sprimary focus is rapid progress toward the commercialization of its two keylead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C andLymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugsare ongoing.
ABthrax(TM) (raxibacumab) is in late-stage development for the treatmentof inhalation anthrax, and the Company is on track to begin the delivery infall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile undera contract entered into with the U.S. Government in June 2006. HGS also hasthree drugs in clinical development for the treatment of cancer, including twoTRAIL receptor antibodies and